°áÀå¾Ï 2±â(Stage II Colon Cancer) ³ëÀÎȯÀÚ¿¡°Ô Ä«Æä½ÃŸºó(capecitabine)°ú 5-fluorouracil (FU) Ä¡·áÀÇ »ýÁ¸À² ºñ±³
Oncologic outcomes after adjuvant chemotherapy with capecitabine compared to 5-fluorouracil/leucovorin for geriatric stage II colon cancer: a retrospective cohort study
[¿¬±¸ Çʿ伺 ]
°áÀå¾Ï 2±â(stage II colon cancer)ÀÇ Ä¡·á Àû ÀýÁ¦¼ú ÈÄ, º¸Á¶ ÈÇÐ ¿ä¹ýÀ¸·Î´Â capecitabine ¶Ç´Â 5-fluorouracil (FU)°ú leucovorin (FL)À» ±ÇÀåµÇ¾î¿Ô´Ù. ¿Á»ì¸®Çöóƾ(oxaliplatin)ÀÇ Ãß°¡´Â ³ªÀÌ°¡ ¸¹Àº ȯÀÚ(70¼¼ ÀÌ»ó)¿¡°Ô´Â È¿°úÀûÀÌÁö ¾ÊÀº °ÍÀ¸·Î ÀÔÁõµÇ¾ú´Ù. ±×·¯¹Ç·Î, capecitabine ¶Ç´Â FLÀº oxaliplatin¾øÀÌ Åõ¿©µÇ´Â °ÍÀÌ ±Ç°íµÇ°í ÀÖ´Ù. °áÀå¾Ï 3±â(stage III colon cancer ) ³ëÀÎȯÀÚ¸¦ ´ë»óÀ¸·Î, capecitabine°ú FLÀÇ Ä¡·á¸¦ ºñ±³ÇÏ¿´À» ¶§, ¹«º´»ýÁ¸À²(disease-free survival)¿¡¼ µ¿µîÇÑ È¿°ú°¡ ÀÖÀ½ÀÌ ¹àÇôÁ³°í ÀÌ Áß capecitabine Åõ¿©°¡ Á» ´õ ÀûÀº ºÎÀÛ¿ëÀÌ ÀÖÀ½ÀÌ º¸°íµÇ¾ú´Ù. ±×·¯³ª, °áÀå¾Ï 2±âÀÇ ³ëÀΠȯÀÚ¸¦ ´ë»óÀ¸·Î capecitabine°ú FL º¸Á¶Ç×¾ÏÈÇпä¹ýÄ¡·á¸¦ ºñ±³ÇÑ Á¾¾çÇÐÀû °á°ú¿¡ ´ëÇÑ Áõ°Å´Â ¾ÆÁ÷±îÁö ¹àÇôÁø ¹Ù°¡ °ÅÀÇ ¾ø´Ù.
[¿¬±¸³»¿ë ¿ä¾à]
ÀÓ»óÁú¹®
|
70¼¼ ÀÌ»óÀÇ 2±â ´ëÀå¾Ï Áø´ÜÀ» ¹ÞÀº ȯÀÚ¿¡°Ô 5-fluorouracil/leucovorin (FL) ȤÀº Capecitabine À» Åõ¿©ÇÑ º¸Á¶Ç×¾ÏÈÇпä¹ý(Adjuvinant chemotherapy)Ä¡·á¿¡¼ »ýÁ¸À²¿¡ Â÷ÀÌ°¡ ÀÖ½À´Ï±î?
|
±Ù°Å±â¹Ý ´äº¯
|
Capecitabine À¸·Î Ä¡·áÇÑ ±×·ì°ú FL ÇÔ¾ÏÁ¦¸¦ Åõ¿©ÇÑ µÎ±º°úÀÇ ºñ±³¿¡¼ ¾ÏƯÈ÷»ýÁ¸À²(Cancer-specific survival, CSS), Àç¹ß»ýÁ¸À²(recurrence-free survival,) Àü¹ÝÀû »ýÁ¸À²(overall survival, OS)¿¡ Â÷ÀÌ°¡ ¾ø¾ú½À´Ï´Ù
|
¼ÁöÁ¤º¸
|
Oncologic outcomes after adjuvant chemotherapy with capecitabine compared to 5-fluorouracil/leucovorin for geriatric stage II colon cancer: a retrospective cohort study (2019). International journal of colorectal disease 2019 Jan ; 87 (2)
|
¿¬±¸¸ñÀû
|
º¸Á¶Ç×¾ÏÈÇпä¹ý(Adjuvant chemotherapy)Ä¡·á¿¡¼ »ýÁ¸À² Â÷ÀÌ ºñ±³ : 5-fluorouracil/leucovorin (FL) vs. Capecitabine
|
¿¬±¸¼³°è
|
ÈÄÇâÀû ÄÚȣƮ¿¬±¸(a retrospective cohort study): 2005³â~2015³â
|
¿¬±¸´ë»ó
|
2±â ´ëÀå¾ÏÁø´ÜÀ» ¹ÞÀº 70¼¼ÀÌ»ó ³ëÀÎ(N=154)
|
½ÃÇ豺 ÁßÀç
|
FL (n=96)
|
´ëÁ¶±º ÁßÀç
|
Capecitabine (n=58)
|
Æò°¡ÁöÇ¥
|
¾ÏƯÈ÷»ýÁ¸À²(Cancer-specific survival, CSS)
Àç¹ß»ýÁ¸À²(recurrence-free survival,)
Àü¹ÝÀû »ýÁ¸À²(overall survival, OS)
|
ÁÖ¿ä°á°ú
|
Kaplan-Meier ºÐ¼®À¸·Î ÃøÁ¤ ÇÑ RFS, CSS ¶Ç´Â OSÀÇ µÎ ±×·ì°£¿¡ Â÷ÀÌ´Â ¾ø¾ú´Ù
( p = 0.763, p = 0.221 ¹× p = 0.470).
|
±Ù°Å¼öÁØ
|
Moderate
|
ÀÛ¼ºÀÚ
|
ÀÇ°úÇבּ¸Á¤º¸¼¾ÅÍ(MedRIC)
Copyright © 2015. Medical Research Information Center (MedRIC) Editors
|
±×¸² 1) Recurrence-free survival. There was no difference in recurrence-free survival between the capecitabine and 5-fluorouracil/leucovorin groups (log-rank p = 0.763)
±×¸²2) Cancer-specific survival. There was no difference in cancer-specific survival between the capecitabine and 5-fluorouracil/leucovorin groups (log-rank p = 0.211)
±×¸² 3) Overall survival. There was no difference in overall survival
between the capecitabine and 5-fluorouracil/leucovorin groups (log-rank p = 0.470)